# ECMM/ISHAM/ASM Global Guideline for Candidiasis

## Metadata
- **Specialty**: Infectious Disease, Critical Care
- **Organization**: European Confederation of Medical Mycology (ECMM), International Society for Human and Animal Mycology (ISHAM), American Society for Microbiology (ASM)
- **Year**: 2024
- **DOI**: [10.1016/S1473-3099(24)00749-7](https://doi.org/10.1016/S1473-3099(24)00749-7)
- **Source URL**: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00749-7/fulltext

## Scope
Global guideline for the diagnosis and management of candidiasis, endorsed by 73 scientific societies including 66 national societies and 7 international societies.

## Key Recommendations

### Epidemiology

#### Common Pathogens
| Species | Characteristics |
|---------|-----------------|
| Candida albicans | Most common, generally susceptible |
| Candida glabrata | Reduced fluconazole susceptibility |
| Candida parapsilosis | Catheter-associated, echinocandin concerns |
| Candida tropicalis | More virulent in some populations |
| Candida auris | Emerging, multidrug resistant |

#### Emerging Threats
- Candida auris (Candidozyma auris): Global health threat
- Fluconazole-resistant C. parapsilosis increasing
- Multidrug resistance patterns emerging

### Diagnosis

#### Blood Cultures
| Aspect | Recommendation |
|--------|----------------|
| Number | At least 2 sets from different sites |
| Volume | Adequate blood volume critical |
| Timing | Before antifungal therapy when possible |
| Follow-up | Daily until clearance documented |

#### Non-Culture Diagnostics
| Test | Use |
|------|-----|
| 1,3-β-D-glucan | Screening, adjunct to cultures |
| Mannan/anti-mannan | Supportive evidence |
| T2Candida | Rapid identification |
| PCR | Species identification |

#### Imaging
- Echocardiography for endocarditis evaluation
- Ophthalmologic exam for ocular candidiasis
- CT/MRI for deep-seated infection

### Treatment

#### First-Line Therapy
| Drug Class | Recommendations |
|------------|-----------------|
| Echinocandins | First-line for candidemia and most invasive candidiasis |
| Rezafungin | New echinocandin option |

#### Echinocandin Options
| Drug | Dosing |
|------|--------|
| Caspofungin | 70 mg load, then 50 mg daily |
| Micafungin | 100 mg daily |
| Anidulafungin | 200 mg load, then 100 mg daily |
| Rezafungin | 400 mg week 1, then 200 mg weekly |

#### Alternative Therapies
| Drug | Indications |
|------|-------------|
| Liposomal amphotericin B | CNS/ocular infection, echinocandin failure |
| Fluconazole | Step-down therapy, susceptible isolates |
| Voriconazole | Specific species, step-down |

### Site-Specific Management

#### Candidemia
| Aspect | Recommendation |
|--------|----------------|
| Initial therapy | Echinocandin |
| Duration | Minimum 2 weeks after clearance |
| Source control | Remove central venous catheters |
| Repeat cultures | Daily until negative |

#### CNS Candidiasis
| Aspect | Recommendation |
|--------|----------------|
| Therapy | Liposomal amphotericin B ± flucytosine |
| Rationale | Echinocandins have poor CNS penetration |
| Duration | Prolonged (weeks to months) |

#### Ocular Candidiasis
| Type | Treatment |
|------|-----------|
| Chorioretinitis without vitritis | Systemic antifungal with good ocular penetration |
| Chorioretinitis with vitritis | Intravitreal antifungal + systemic therapy |
| Agents | Liposomal amphotericin B, voriconazole, fluconazole |

#### Endocarditis
| Aspect | Recommendation |
|--------|----------------|
| Medical therapy | Echinocandin or liposomal amphotericin B |
| Surgery | Early surgical intervention recommended |
| Duration | Minimum 6 weeks after surgery |
| Suppression | Long-term fluconazole may be needed |

#### Intra-Abdominal Candidiasis
| Aspect | Recommendation |
|--------|----------------|
| Source control | Essential (drainage, debridement) |
| Antifungal | Echinocandin preferred |
| Duration | Individualized based on source control |

### Candida auris

#### Special Considerations
| Aspect | Recommendation |
|--------|----------------|
| Infection control | Contact precautions, enhanced cleaning |
| Susceptibility testing | Required due to resistance |
| First-line | Echinocandin (if susceptible) |
| Resistance | May require combination therapy |

### Step-Down Therapy

#### Transition to Oral
| Criteria | Requirements |
|----------|--------------|
| Clinical improvement | Afebrile, stable |
| Culture clearance | Negative blood cultures |
| Species susceptibility | Fluconazole or voriconazole susceptible |
| Oral absorption | GI tract functional |

#### Oral Options
| Drug | Indication |
|------|------------|
| Fluconazole | Susceptible C. albicans, tropicalis, parapsilosis |
| Voriconazole | Fluconazole-resistant isolates |
| Posaconazole | Selected resistant cases |

### Duration of Therapy

#### By Syndrome
| Syndrome | Duration |
|----------|----------|
| Uncomplicated candidemia | 2 weeks after first negative culture |
| Metastatic complications | Extended based on site |
| Endocarditis | ≥6 weeks post-surgery |
| Osteomyelitis | 6-12 months |

### Antifungal Resistance

#### Testing
- Species identification critical
- Susceptibility testing recommended
- EUCAST or CLSI methods

#### Resistance Patterns
| Species | Common Resistance |
|---------|-------------------|
| C. glabrata | Fluconazole intrinsic resistance |
| C. krusei | Fluconazole intrinsic resistance |
| C. auris | Variable multi-drug resistance |

### Prevention

#### Prophylaxis Indications
| Population | Recommendation |
|------------|----------------|
| High-risk hematology | Consider prophylaxis |
| ICU patients | Not routine |
| Post-transplant | Per transplant guidelines |

